1921
image of Effect Modification by Baseline Mortality in the MORDOR Azithromycin Trial
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

We examined whether baseline mortality risk, as a function of child age and site, modified the azithromycin mortality-reduction effect in the (MORDOR) clinical trial. We used the Cox proportional hazards model with an interaction term. Three models were examined representing three sources for the baseline-risk covariate: two using sources external to MORDOR and the third leveraging data within MORDOR. All three models provided moderate evidence for the effect becoming stronger with increasing baseline mortality ( = 0.02, 0.02, and 0.07, respectively) at the rate of approximately 6–12% additional mortality reduction per doubling of baseline mortality. Etiological and programmatic implications of these findings are discussed.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.18-1004
2019-02-07
2019-11-19
Loading full text...

Full text loading...

http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.18-1004
Loading
  • Received : 25 Dec 2018
  • Accepted : 23 Jan 2019
  • Published online : 07 Feb 2019
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error